These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 36109825)

  • 1. Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial.
    Franco-Moreno A; Acedo-Gutiérrez MS; Martín NL; Hernández-Blanco C; Rodríguez-Olleros C; Ibáñez-Estéllez F; Suárez-Simón A; Balado-Rico M; Romero-Paternina AR; Alonso-Menchén D; Escolano-Fernández B; Piniella-Ruiz E; Alonso-Monge E; Notario-Leo H; Bibiano-Guillén C; Peña-Lillo G; Antiqueira-Pérez A; Romero-Pareja R; Cabello-Clotet N; Estrada-Pérez V; Troya-García J; de Carranza-López M; Escobar-Rodríguez I; Vallejo-Maroto N; Torres-Macho J
    Trials; 2022 Sep; 23(1):784. PubMed ID: 36109825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of early administration of dexamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome: EARLY-DEX COVID-19 trial.
    Franco-Moreno A; Acedo-Gutiérrez MS; Casado-Suela MÁ; Labrador-San Martín N; de Carranza-López M; Ibáñez-Estéllez F; Hernández-Blanco C; Jiménez-Torres J; Vallejo-Maroto I; Romero-Pareja R; Peña-Lillo G; Escobar-Rodríguez I; Torres-Macho J;
    Front Med (Lausanne); 2024; 11():1385833. PubMed ID: 39086948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial.
    Villar J; Añón JM; Ferrando C; Aguilar G; Muñoz T; Ferreres J; Ambrós A; Aldecoa C; Suárez-Sipmann F; Thorpe KE; Jüni P; Slutsky AS;
    Trials; 2020 Aug; 21(1):717. PubMed ID: 32799933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial.
    Maskin LP; Olarte GL; Palizas F; Velo AE; Lurbet MF; Bonelli I; Baredes ND; Rodríguez PO
    Trials; 2020 Aug; 21(1):743. PubMed ID: 32843098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trial.
    Tomazini BM; Maia IS; Bueno FR; Silva MVAO; Baldassare FP; Costa ELV; Moura RAB; Honorato MO; Costa AN; Cavalcanti AB; Rosa RG; Avezum Á; Veiga VC; Lopes RD; Damiani LP; Machado FR; Berwanger O; Azevedo LCP;
    Rev Bras Ter Intensiva; 2020; 32(3):354-362. PubMed ID: 33053024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial.
    Abdolahi N; Kaheh E; Golsha R; Khodabakhshi B; Norouzi A; Khandashpoor M; Besharat S; Tavassoli S; Livani S; Azimi SA; Gharib MH; Peivandi B; Fazel A; Shirzad-Aski H; Roshandel G
    Trials; 2020 Jun; 21(1):549. PubMed ID: 32560745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.
    Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of corticosteroids in patients with COVID-19 early stage pneumonia and risk of disease progression: An uncharted territory.
    Franco-Moreno A; Acedo-Gutiérrez MS; Romero-Pareja R; Torres-Macho J
    Drug Discov Ther; 2022; 16(1):47-48. PubMed ID: 35264475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)-study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2022 Jan; 23(1):35. PubMed ID: 35033182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
    Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
    Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.
    Tomazini BM; Maia IS; Cavalcanti AB; Berwanger O; Rosa RG; Veiga VC; Avezum A; Lopes RD; Bueno FR; Silva MVAO; Baldassare FP; Costa ELV; Moura RAB; Honorato MO; Costa AN; Damiani LP; Lisboa T; Kawano-Dourado L; Zampieri FG; Olivato GB; Righy C; Amendola CP; Roepke RML; Freitas DHM; Forte DN; Freitas FGR; Fernandes CCF; Melro LMG; Junior GFS; Morais DC; Zung S; Machado FR; Azevedo LCP;
    JAMA; 2020 Oct; 324(13):1307-1316. PubMed ID: 32876695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.